I have been in finance for 30+ years. Question, when considering revenues I would like to know what percentage you allotted to a big pharma partner for their distributions and sales efforts. Secondly, did you account for Anavex' annual operating expenses including any continuing R&D costs? I think if you calculate 15-20% of top line revenues as bottom line net income distributable to shareholders as desired (or, in all likelihood, retained within the company) that would be much more realistic. You can create two scenarios: The EU only with a realistic penetration as % of 7MM patients and another with the US included as well as Canada, Gt. Britain and Australia to start. Good luck. Let me know your net numbers, or rather, the board and include percentage of population on Blar.
Market Data 
Markets 
